Distinct Roles for Histone Methyltransferases G9a and GLP in Cancer Germ-line Antigen Gene Regulation in Human Cancer Cells and Murine Embryonic Stem Cells

Overview

Journal Mol Cancer Res

Specialty Cell Biology

Date 2009 Jun 18

PMID 19531572

Citations 37

Authors

Petra A Link

Omkaram Gangisetty

Smitha R James

Anna Woloszynska-Read

Makoto Tachibana

Yoichi Shinkai

Adam R Karpf

Affiliations

Soon will be listed here.

Abstract

The H3K9me2 histone methyltransferases G9a and GLP repress Mage-a class cancer germ-line (CG) antigen gene expression in murine embryonic stem (ES) cells, but the role of these enzymes in CG antigen gene regulation in human cancer cells is unknown. Here we show that whereas independent or dual knockdown of G9a and GLP in human cancer cells leads to reduced global and CG antigen promoter-associated H3K9me2 levels, it does not activate CG antigen gene expression. Moreover, CG antigen gene repression is maintained following pharmacologic targeting of G9a or treatment of G9a knockdown cells with the histone deacetylase inhibitor trichostatin A. However, G9a knockdown cells display increased sensitivity to CG antigen gene activation mediated by the DNA methyltransferase inhibitor decitabine. To account for these findings, we examined DNA methylation at CG antigen gene promoters in both cell types. We found robust DNA hypomethylation in G9a/GLP targeted murine ES cells but a lack of DNA methylation changes in G9a/GLP targeted human cancer cells; intriguingly, this distinction also extended to markers of global DNA methylation. These data reveal that G9a/GLP is required for DNA methylation of CG antigen genes and genomic DNA in murine ES cells, but not human cancer cells, and implicate DNA methylation status as the key epigenetic mechanism involved in CG antigen gene repression.

Citing Articles

The potential value of cancer-testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy.

Lin L, Zou X, Nong W, Ge Y, Li F, Luo B Immun Inflamm Dis. 2024; 12(6):e1284.

PMID: 38896069 PMC: 11186301. DOI: 10.1002/iid3.1284.

Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome.

Wang S, Xiong Y, Jang M, Park K, Donahue M, Velez J Mol Ther. 2024; 32(8):2662-2675.

PMID: 38796700 PMC: 11405540. DOI: 10.1016/j.ymthe.2024.05.034.

Discovery of the First-in-Class G9a/GLP PROTAC Degrader.

Velez J, Han Y, Yim H, Yang P, Deng Z, Park K J Med Chem. 2024; 67(8):6397-6409.

PMID: 38602846 PMC: 11069390. DOI: 10.1021/acs.jmedchem.3c02394.

Discovery of the First-in-class G9a/GLP PROTAC Degrader.

Velez J, Han Y, Yim H, Yang P, Deng Z, Park K bioRxiv. 2024; .

PMID: 38464025 PMC: 10925177. DOI: 10.1101/2024.02.26.582210.

A Review of Advanced Cutaneous Melanoma Therapies and Their Mechanisms, from Immunotherapies to Lysine Histone Methyl Transferase Inhibitors.

de Oliveira Filho R, de Oliveira D, Nisimoto M, Marti L Cancers (Basel). 2023; 15(24).

PMID: 38136297 PMC: 10741407. DOI: 10.3390/cancers15245751.

References

Collins R, Tachibana M, Tamaru H, Smith K, Jia D, Zhang X . In vitro and in vivo analyses of a Phe/Tyr switch controlling product specificity of histone lysine methyltransferases. J Biol Chem. 2004; 280(7):5563-70. PMC: 2696276. DOI: 10.1074/jbc.M410483200. View

Esteve P, Patnaik D, Chin H, Benner J, Teitell M, Pradhan S . Functional analysis of the N- and C-terminus of mammalian G9a histone H3 methyltransferase. Nucleic Acids Res. 2005; 33(10):3211-23. PMC: 1143580. DOI: 10.1093/nar/gki635. View

Xin Z, Tachibana M, Guggiari M, Heard E, Shinkai Y, Wagstaff J . Role of histone methyltransferase G9a in CpG methylation of the Prader-Willi syndrome imprinting center. J Biol Chem. 2003; 278(17):14996-5000. DOI: 10.1074/jbc.M211753200. View

Lachner M, OSullivan R, Jenuwein T . An epigenetic road map for histone lysine methylation. J Cell Sci. 2003; 116(Pt 11):2117-24. DOI: 10.1242/jcs.00493. View

Chin H, Pradhan M, Esteve P, Patnaik D, Evans Jr T, Pradhan S . Sequence specificity and role of proximal amino acids of the histone H3 tail on catalysis of murine G9A lysine 9 histone H3 methyltransferase. Biochemistry. 2005; 44(39):12998-3006. DOI: 10.1021/bi0509907. View

Cameron E, Bachman K, Myohanen S, Herman J, Baylin S . Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999; 21(1):103-7. DOI: 10.1038/5047. View

Colella S, Shen L, Baggerly K, Issa J, Krahe R . Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques. 2003; 35(1):146-50. DOI: 10.2144/03351md01. View

Wischnewski F, Friese O, Pantel K, Schwarzenbach H . Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol Cancer Res. 2007; 5(7):749-59. DOI: 10.1158/1541-7786.MCR-06-0364. View

Sigalotti L, Coral S, Fratta E, Lamaj E, Danielli R, Di Giacomo A . Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin Oncol. 2005; 32(5):473-8. DOI: 10.1053/j.seminoncol.2005.07.005. View

10.

Kubicek S, OSullivan R, August E, Hickey E, Zhang Q, Teodoro M . Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007; 25(3):473-81. DOI: 10.1016/j.molcel.2007.01.017. View

11.

De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T . The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A. 1996; 93(14):7149-53. PMC: 38951. DOI: 10.1073/pnas.93.14.7149. View

12.

Woloszynska-Read A, James S, Link P, Yu J, Odunsi K, Karpf A . DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun. 2007; 7:21. PMC: 2935752. View

13.

Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M . G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 2002; 16(14):1779-91. PMC: 186403. DOI: 10.1101/gad.989402. View

14.

De Smet C, Loriot A, Boon T . Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. Mol Cell Biol. 2004; 24(11):4781-90. PMC: 416434. DOI: 10.1128/MCB.24.11.4781-4790.2004. View

15.

Ikegami K, Iwatani M, Suzuki M, Tachibana M, Shinkai Y, Tanaka S . Genome-wide and locus-specific DNA hypomethylation in G9a deficient mouse embryonic stem cells. Genes Cells. 2007; 12(1):1-11. DOI: 10.1111/j.1365-2443.2006.01029.x. View

16.

Simpson A, Caballero O, Jungbluth A, Chen Y, Old L . Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005; 5(8):615-25. DOI: 10.1038/nrc1669. View

17.

Rozen S, Skaletsky H . Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 1999; 132:365-86. DOI: 10.1385/1-59259-192-2:365. View

18.

Li E, Bestor T, Jaenisch R . Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell. 1992; 69(6):915-26. DOI: 10.1016/0092-8674(92)90611-f. View

19.

Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf A . Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res. 2008; 14(11):3283-90. PMC: 2835568. DOI: 10.1158/1078-0432.CCR-07-5279. View

20.

Herman J, Graff J, Myohanen S, Nelkin B, Baylin S . Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93(18):9821-6. PMC: 38513. DOI: 10.1073/pnas.93.18.9821. View